title: Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study
creator: Wallwiener, Markus
creator: Nabieva, Naiba
creator: Feisst, Manuel
creator: Fehm, Tanja
creator: de Waal, Johann
creator: Rezai, Mahdi
creator: Baier, Bernd
creator: Baake, Gerold
creator: Kolberg, Hans-Christian
creator: Guggenberger, Martin
creator: Warm, Mathias
creator: Harbeck, Nadia
creator: Wuerstlein, Rachel
creator: Deuker, Jörg-Uwe
creator: Dall, Peter
creator: Richter, Barbara
creator: Wachsmann, Grischa
creator: Brucker, Cosima
creator: Siebers, Jan Willem
creator: Popovic, Milos
creator: Kuhn, Thomas
creator: Wolf, Christopher
creator: Vollert, Hans-Walter
creator: Breitbach, Georg-Peter
creator: Janni, Wolfgang
creator: Landthaler, Robert
creator: Kohls, Andreas
creator: Rezek, Daniela
creator: Noesselt, Thomas
creator: Fischer, Gunnar
creator: Henschen, Stephan
creator: Praetz, Thomas
creator: Heyl, Volker
creator: Kühn, Thorsten
creator: Krauss, Thomas
creator: Thomssen, Christoph
creator: Hohn, Andre
creator: Tesch, Hans
creator: Mundhenke, Christoph
creator: Hein, Alexander
creator: Rauh, Claudia
creator: Bayer, Christian M.
creator: Schmidt, Katja
creator: Belleville, Erik
creator: Brucker, Sara Y.
creator: Hadji, Peyman
creator: Beckmann, Matthias W.
creator: Wallwiener, Diethelm
creator: Kümmel, Sherko
creator: Hartkopf, Andreas
creator: Fasching, Peter A.
subject: 610
subject: 610 Medical sciences Medicine
description: Background: Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients.    Methods: EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor–positive breast cancer. To assess therapy persistence, defined as the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and 12 months. Competing risk survival analyses were performed to identify patient and tumor characteristics that predict TTEOT.    Results: Out of 200 patients, 66 patients terminated treatment prematurely, 26 (13%) of them due to causes other than disease progression. Persistence rate for reasons other than progression at 12 months was 77.7%. Persistence was lower in patients who reported any adverse event (AE) in the first 30 days of ET (89.5% with no AE and 56% with AE). Furthermore, patients had a lower persistence if they reported compliance problems in the past before letrozole treatment.       Conclusions: Despite suffering from a life-threatening disease, AEs of an AI will result in a relevant number of treatment terminations that are not related to progression. Some subgroups of patients have very low persistence rates. Especially with regard to novel endocrine combination therapies, these data imply that some groups of patients will need special attention to guide them through the therapy process.    Trial registration Clinical Trials Number: CFEM345DDE19
publisher: BioMed Central ; Springer
date: 2019
type: Article
type: info:eu-repo/semantics/article
type: NonPeerReviewed
format: application/pdf
identifier: https://archiv.ub.uni-heidelberg.de/volltextserverhttps://archiv.ub.uni-heidelberg.de/volltextserver/26657/1/12885_2019_Article_5806.pdf
identifier: DOI:
identifier: urn:nbn:de:bsz:16-heidok-266570
identifier:   Wallwiener, Markus ; Nabieva, Naiba ; Feisst, Manuel ; Fehm, Tanja ; de Waal, Johann ; Rezai, Mahdi ; Baier, Bernd ; Baake, Gerold ; Kolberg, Hans-Christian ; Guggenberger, Martin ; Warm, Mathias ; Harbeck, Nadia ; Wuerstlein, Rachel ; Deuker, Jörg-Uwe ; Dall, Peter ; Richter, Barbara ; Wachsmann, Grischa ; Brucker, Cosima ; Siebers, Jan Willem ; Popovic, Milos ; Kuhn, Thomas ; Wolf, Christopher ; Vollert, Hans-Walter ; Breitbach, Georg-Peter ; Janni, Wolfgang ; Landthaler, Robert ; Kohls, Andreas ; Rezek, Daniela ; Noesselt, Thomas ; Fischer, Gunnar ; Henschen, Stephan ; Praetz, Thomas ; Heyl, Volker ; Kühn, Thorsten ; Krauss, Thomas ; Thomssen, Christoph ; Hohn, Andre ; Tesch, Hans ; Mundhenke, Christoph ; Hein, Alexander ; Rauh, Claudia ; Bayer, Christian M. ; Schmidt, Katja ; Belleville, Erik ; Brucker, Sara Y. ; Hadji, Peyman ; Beckmann, Matthias W. ; Wallwiener, Diethelm ; Kümmel, Sherko ; Hartkopf, Andreas ; Fasching, Peter A.  (2019) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.  BMC cancer, 16 (611).  pp. 1-9.  ISSN 1471-2407     
relation: https://archiv.ub.uni-heidelberg.de/volltextserver/26657/
rights: info:eu-repo/semantics/openAccess
rights: Please see front page of the work (Sorry, Dublin Core plugin does not recognise license id)
language: eng